A Phase 2 interventional study of Insulin Lispro and regular human insulin in Diabetes Mellitus, Type 1, sponsored by Halozyme Therapeutics. Completed at 8 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-09-08.
Sponsored by Halozyme Therapeutics · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 31st largest by enrollment, is the only one that started in 2009, is one of 7 in phase 2, and was the 11th registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
By country, each count listing its studies:
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2002; this study’s year is marked. 1 started in 2009.
This study's enrollment of 48 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 69 interventional studies. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 69 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 7 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
1 of the studies testing Insulin Lispro in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other injectable drugs. In this study, rHuPH20 combined with a non-preserved (NP) formulation of regular human insulin (INSULIN-PH20 NP) will be compared to insulin lispro with respect to absorption and action of insulin.
The purpose of this study is to compare the safety and tolerability of INSULIN-PH20 NP versus insulin lispro alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled participants underwent a 1-month dose titration period and received 100 units per milliliter (U/mL) insulin lispro, injected subcutaneously (SC) pre-meals, with doses titrated to each participant individually. Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle. INSULIN-PH20 NP (Treatment A): 100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, doses titrated to each participant individually. Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, doses titrated to each participant individually. Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine or maintained their usual regimen through an insulin pump.
Drug: Insulin Lispro · Drug: regular human insulin · Drug: recombinant human hyaluronidase PH20 · Drug: Insulin glargine
Also known as: Humalog
Also known as: Humulin R
Also known as: Hylenex, rHuPH20, PH20
Also known as: Lantus
Postprandial Glucose Excursion
A 2-hour postprandial glucose excursion was measured for 3 meals over 3 days during each treatment cycle (3 days during Week 14 of the first treatment cycle and 3 days during Week 26 of the second treatment cycle). For each of the 3 days, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal value as determined by 8-point glucose monitoring. The average of all excursions over the 3 days for the corresponding treatment cycle is presented.
Time frame: Week 14 and Week 26
Time Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring
Participants were provided a continuous glucose monitoring (CGM) device, consisting of a sensor, transmitter, and receiver. Total time the participant's blood glucose was outside the 71-139 mg/dL range during 3 days of CGM during each treatment cycle (3 days during Week 14 of the first treatment cycle and 3 days during Week 26 of the second treatment cycle) is presented.
Time frame: Week 14 and Week 26
Number of Participants With Hypoglycemic Events
The number of participants with at least one hypoglycemic event (HE) reported during the entire study is presented. Additionally, the number of participants with severe HEs (those that necessitated administration of carbohydrate or glucagon, or resuscitation, by another person) is also presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through Week 29
| Milestone | All Enrolled Participants | INSULIN-PH20 NP First, Then Insulin Lispro | Insulin Lispro First, Then INSULIN-PH20 NP |
|---|---|---|---|
| Started | 48 | 0 | 0 |
| Completed | 46 | 0 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Milestone | All Enrolled Participants | INSULIN-PH20 NP First, Then Insulin Lispro | Insulin Lispro First, Then INSULIN-PH20 NP |
|---|---|---|---|
| Started | 0 | 22 | 24 |
| Received at least 1 dose of study drug | 0 | 22 | 24 |
| Completed | 0 | 19 | 23 |
| Not completed | 0 | 3 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Milestone | All Enrolled Participants | INSULIN-PH20 NP First, Then Insulin Lispro | Insulin Lispro First, Then INSULIN-PH20 NP |
|---|---|---|---|
| Started | 0 | 19 | 23 |
| Received at least 1 dose of study drug | 0 | 19 | 23 |
| Completed | 0 | 19 | 22 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
A 2-hour postprandial glucose excursion was measured for 3 meals over 3 days during each treatment cycle (3 days during Week 14 of the first treatment cycle and 3 days during Week 26 of the second treatment cycle). For each of the 3 days, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal value as determined by 8-point glucose monitoring. The average of all excursions over the 3 days for the corresponding treatment cycle is presented.
| milligrams per deciliter (mg/dL) | INSULIN-PH20 NP | Insulin Lispro |
|---|---|---|
| Postprandial Glucose Excursion | 17.23 ± 36.040 | 14.47 ± 35.113 |
Participants were provided a continuous glucose monitoring (CGM) device, consisting of a sensor, transmitter, and receiver. Total time the participant's blood glucose was outside the 71-139 mg/dL range during 3 days of CGM during each treatment cycle (3 days during Week 14 of the first treatment cycle and 3 days during Week 26 of the second treatment cycle) is presented.
| hours | INSULIN-PH20 NP | Insulin Lispro |
|---|---|---|
| Time Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring | 14.58 ± 3.155 | 13.37 ± 3.933 |
The number of participants with at least one hypoglycemic event (HE) reported during the entire study is presented. Additionally, the number of participants with severe HEs (those that necessitated administration of carbohydrate or glucagon, or resuscitation, by another person) is also presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | INSULIN-PH20 NP | Insulin Lispro |
|---|---|---|
| Overall | 45 | 43 |
| Severe HE | 2 | 0 |
Collected over An adverse event was considered treatment-emergent if the start date of the event was on or after the date of randomization.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| INSULIN-PH20 NP Treatment Period | — | 2/45 (4.4%) | 17/45 (37.8%) |
| Insulin Lispro Treatment Period | — | 1/43 (2.3%) | 11/43 (25.6%) |
| Event | INSULIN-PH20 NP Treatment Period | Insulin Lispro Treatment Period |
|---|---|---|
| Uterine haemorrhageReproductive system and breast disorders | 1/22 | 0/20 |
| HaemothoraxInjury, poisoning and procedural complications | 0/45 | 1/43 |
| Rib fractureInjury, poisoning and procedural complications | 0/45 | 1/43 |
| Intervertebral disc degenerationMusculoskeletal and connective tissue disorders | 1/45 | 0/43 |
| Event | INSULIN-PH20 NP Treatment Period | Insulin Lispro Treatment Period |
|---|---|---|
| NasopharyngitisInfections and infestations | 7/45 | 7/43 |
| Upper respiratory tract infectionInfections and infestations | 1/45 | 3/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/45 | 0/43 |
| Food poisoningGastrointestinal disorders | 0/45 | 2/43 |
| Back painMusculoskeletal and connective tissue disorders | 0/45 | 2/43 |
| SinusitisInfections and infestations | 2/45 | 1/43 |
| BronchitisInfections and infestations | 2/45 | 0/43 |
| Fungal infectionInfections and infestations | 2/45 | 1/43 |
| Injection site haematomaGeneral disorders | 2/45 | 1/43 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/45 | 0/43 |
Participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | All Randomized Participants |
|---|---|
| Mean | 41.6 ± 13.28 |
| Sex: Female, Male(Participants) | All Randomized Participants |
|---|---|
| Female | 22 |
| Male | 24 |
| Race (NIH/OMB)(Participants) | All Randomized Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 44 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | All Randomized Participants |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 44 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | All Randomized Participants |
|---|---|
| United States | 46 |
The record gives a start of May 2009, a primary completion of Feb 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Lispro · Hyaluronidase (human recombinant)